International Stem Cell (ISCO) Capital Expenditures (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Capital Expenditures of $3000.0 for Q4 2025, down 98.18% year-over-year from $165000.0 in Q4 2024, and little changed quarter-over-quarter from $3000.0 in Q3 2025.
International Stem Cell (ISCO) Capital Expenditures (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Capital Expenditures for 15 consecutive years, with $3000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 98.18% year-over-year to $3000.0; the TTM figure through Dec 2025 stood at $43000.0 (down 74.1% YoY), while the FY2025 annual figure was $43000.0, down 74.1% from the prior year.
- Capital Expenditures was little changed at $3000.0 in Q4 2025 per ISCO's latest filing, from $3000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $165000.0 in Q4 2024 and bottomed at -$127000.0 in Q3 2024.
- Historically, Capital Expenditures has averaged $24916.7 across 4 years, with a median of $12000.0 in 2021.
- Annual changes were most pronounced in 2021 — Capital Expenditures surged 150.0% — and 2024, when it tumbled 1007.14%.
- International Stem Cell's Capital Expenditures stood at $10000.0 in 2021, then jumped by 40.0% to $14000.0 in 2023, then jumped by 1078.57% to $165000.0 in 2024, then plunged by 98.18% to $3000.0 in 2025.
- Business Quant data shows ISCO's Capital Expenditures at $3000.0 in Q4 2025, $3000.0 in Q3 2025, and $32000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Sep 30, 2024 | -127,000.00 |
| Sep 30, 2024 | -127,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Jun 30, 2023 | 51,000.00 |